Hum. Reprod. Advance Access originally published online on July 22, 2004
Human Reproduction 2004 19(10):2200-2205; doi:10.1093/humrep/deh415
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Half-dose depot triptorelin in pituitary suppression for multiple ovarian stimulation in assisted reproduction technology: a randomized study*
1 Tecnobios Procreazione, Center for Reproductive Health, Via Dante 15, I-40125 Bologna, Italy and 2 University of Bologna, Bologna, Italy
3 To whom correspondence should be addressed. Email: borini{at}tecnobios.it
BACKGROUND: Pituitary suppression by depot GnRH agonist may be excessive for ovarian stimulation in assisted reproduction technology. This study compares the efficacy of standard and half-dose depot triptorelin in a long protocol. METHODS: A total of 180 patients were randomized into two groups using sealed envelopes. Pituitary desensitization was obtained in group 1 (90 patients) with half-dose (1.87 mg) triptorelin depot in the mid-luteal phase of their menstrual cycle, and in group 2 (90 patients) with full-dose (3.75 mg) triptorelin. RESULTS: There was no premature LH surge, with LH levels being lower in the full-dose group (1.04±0.05 versus 0.7±0.06 IU/l on the day of hCG). The number of FSH ampoules used was lower in group 1 (42±2 versus 59±3). The numbers of mature oocytes (10.1±0.54 versus 7.4±0.55), of fertilized oocytes (8.24±0.35 versus 6.34±0.37) and of embryos (7.8±0.36 versus 5.9±0.37) were significantly higher in group 1. No significant differences were found in pregnancy (38.8 versus 25.3%), implantation (22.6 versus 13.8%) or abortion (6.1 versus 5.0%) rates. Cumulative pregnancy (fresh plus frozen embryo transfers: 56.8 versus 35.4%) rate was significantly higher in group 1. CONCLUSION: A half-dose of depot triptorelin can be successfully used in ovarian stimulation for IVF and produce a higher number of good quality embryos with a good chance of implantation.
Key words: GnRH-agonist/half-dose/IVF/ovarian stimulation/triptorelin
* Presented in part at the 18th Annual Meeting of ESHRE, June 30–July 3, 2002, Vienna, Austria
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  L. Safdarian, F. S. Mohammadi, A. Alleyassin, M. Aghahosseini, A. Meysamie, and E. Rahimi Clinical outcome with half-dose depot triptorelin is the same as reduced-dose daily buserelin in a long protocol of controlled ovarian stimulation for ICSI/embryo transfer: a randomized double-blind clinical trial (NCT00461916) Hum. Reprod., September 1, 2007; 22(9): 2449 - 2454. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Isikoglu, S. Ozdem, M. Berkkanoglu, H. Jamal, Z. Senturk, and K. Ozgur Single-dose depot leuprolide is as efficient as daily short-acting leuprolide in ICSI cycles Hum. Reprod., June 1, 2007; 22(6): 1657 - 1661. [Abstract] [Full Text] [PDF]
|
|